Needham & Company LLC Reaffirms “Buy” Rating for Stoke Therapeutics (NASDAQ:STOK)

Stoke Therapeutics (NASDAQ:STOK)‘s stock had its “buy” rating reissued by equities researchers at Needham & Company LLC in a report released on Tuesday,Benzinga reports. They presently have a $22.00 target price on the stock. Needham & Company LLC’s target price would indicate a potential upside of 152.00% from the company’s current price.

Other analysts have also recently issued research reports about the stock. HC Wainwright upped their price objective on shares of Stoke Therapeutics from $35.00 to $47.00 and gave the company a “buy” rating in a research report on Tuesday, February 18th. Chardan Capital reaffirmed a “buy” rating and issued a $24.00 target price on shares of Stoke Therapeutics in a research note on Wednesday, February 19th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Stoke Therapeutics in a research note on Tuesday, December 10th. One investment analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Stoke Therapeutics currently has a consensus rating of “Buy” and an average price target of $23.00.

Stoke Therapeutics Stock Down 3.0 %

Shares of STOK traded down $0.27 during trading hours on Tuesday, reaching $8.73. The stock had a trading volume of 704,344 shares, compared to its average volume of 822,816. Stoke Therapeutics has a 52 week low of $5.60 and a 52 week high of $17.58. The firm has a 50-day moving average of $9.53 and a 200 day moving average of $11.58. The company has a market cap of $462.40 million, a P/E ratio of -4.15 and a beta of 0.99.

Stoke Therapeutics (NASDAQ:STOK) last released its quarterly earnings data on Monday, March 24th. The company reported ($0.18) EPS for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.38. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%. As a group, equities analysts expect that Stoke Therapeutics will post -2.01 earnings per share for the current year.

Hedge Funds Weigh In On Stoke Therapeutics

A number of large investors have recently modified their holdings of the business. Bank of New York Mellon Corp boosted its stake in shares of Stoke Therapeutics by 1.4% during the 4th quarter. Bank of New York Mellon Corp now owns 93,195 shares of the company’s stock worth $1,028,000 after buying an additional 1,330 shares during the last quarter. Graham Capital Management L.P. boosted its stake in shares of Stoke Therapeutics by 8.5% during the 4th quarter. Graham Capital Management L.P. now owns 18,634 shares of the company’s stock worth $206,000 after buying an additional 1,453 shares during the last quarter. Gilder Gagnon Howe & Co. LLC boosted its stake in shares of Stoke Therapeutics by 2.0% during the 4th quarter. Gilder Gagnon Howe & Co. LLC now owns 92,546 shares of the company’s stock worth $1,021,000 after buying an additional 1,791 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its stake in Stoke Therapeutics by 6.3% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 37,455 shares of the company’s stock valued at $414,000 after purchasing an additional 2,215 shares during the last quarter. Finally, Rhumbline Advisers grew its holdings in Stoke Therapeutics by 6.0% during the fourth quarter. Rhumbline Advisers now owns 49,374 shares of the company’s stock worth $545,000 after purchasing an additional 2,787 shares during the period.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.